Glaukos Corporation reported $613M of revenue over the trailing twelve months, +42% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $613M (to Q2 2026). Net income: −$188M, trailing twelve months to Q2 2026. Free cash flow: −$12M, trailing twelve months to Q2 2026. Operating margin: −33%, trailing twelve months to Q2 2026.

GKOSGlaukos Corporation

Healthcare

$165.63+98% 1Y

$165.63

$74.6752 weeks$189.58

GKOS as reported

Glaukos Corporation reported $613M of revenue over the trailing twelve months, +42% on the year before. 10 reported series are charted on this page, each one as filed.

$613M

Revenue, trailing twelve months · to Q2 2026 · +42% against the twelve months before

Net income: −$188M
Net income · +103% year on year · trailing twelve months to Q2 2026
Free cash flow: −$12M
Free cash flow · −55% year on year · trailing twelve months to Q2 2026
Operating margin: −33%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for GKOS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$613M	+42%	Q2 2026
Net income	−$188M	+103%	Q2 2026
EPS	−$3.26	+99%	Q2 2026
Gross margin	59%	n/a	Q2 2026
Operating margin	−33%	n/a	Q2 2026
Net margin	−32%	n/a	Q2 2026
ROE	−24%	n/a	Q2 2026
ROA	−18%	n/a	Q2 2026
ROIC	−4.1%	n/a	Q3 2016 · 39 quarters behind
Free cash flow	−$12M	−55%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.